

1 Title: **Evidence of a noncoding transcript of the *RIPK2* gene overexpressed in head and**  
2 **neck tumor**

3  
4  
5 **Authors:**

6 Ulises M. M. Villagra<sup>1&</sup>; Bianca R. da Cunha<sup>2,3&</sup>; Giovana M. Polachini<sup>2</sup>; Tiago Henrique<sup>2</sup>;  
7 Carlos H. T. P. da Silva<sup>4</sup>; Olavo A. Feitosa<sup>4</sup>; Erica E. Fukuyama<sup>5</sup>; Rossana V. M. López<sup>6</sup>;  
8 Emmanuel Dias-Neto<sup>7,8</sup>; Fabio D. Nunes<sup>9</sup>; Patricia Severino<sup>10</sup> and Eloiza H. Tajara<sup>2,3\*</sup>

9  
10  
11 **Affiliations:**

12 <sup>1</sup>Faculty of Exact Sciences, Biotechnology and Molecular Biology Institute (IBBM), National  
13 University of La Plata-CCT, CONICET, La Plata, Argentina

14 <sup>2</sup>Department of Molecular Biology, School of Medicine of São José do Rio Preto/FAMERP,  
15 São José do Rio Preto, SP, Brazil

16 <sup>3</sup>Department of Genetics and Evolutionary Biology, Institute of Biosciences, University of São  
17 Paulo/USP, São Paulo, SP, Brazil

18 <sup>4</sup>Computational Laboratory of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences  
19 of Ribeirão Preto, University of São Paulo/USP, Ribeirão Preto, SP, Brazil

20 <sup>5</sup>Head and Neck Surgery Department, Arnaldo Vieira de Carvalho Cancer Institute, São Paulo,  
21 SP, Brazil

22 <sup>6</sup>State of São Paulo Cancer Institute – ICESP, SP, São Paulo, Brazil

23 <sup>7</sup>Laboratory of Medical Genomics, A. C. Camargo Cancer Center, São Paulo, SP, Brazil

24 <sup>8</sup>Laboratory of Neurosciences, Institute of Psychiatry, University of São Paulo/USP, São  
25 Paulo, SP, Brazil

26 <sup>9</sup>Department of Stomatology, School of Dentistry, University of São Paulo/USP, São Paulo,  
27 SP, Brazil.

28 <sup>10</sup>Albert Einstein Research and Education Institute, Hospital Israelita Albert Einstein, São  
29 Paulo, SP, Brazil

30  
31  
32  
33 **\*Corresponding author:**

34 E-mail: [tajara@famerp.br](mailto:tajara@famerp.br) (EHT)

35  
36 **&**These authors contributed equally to this work.

## 38 **ABSTRACT**

39        Receptor-interacting proteins are a family of serine/threonine kinases, which integrate  
40 extra and intracellular stress signals caused by different factors, including infections,  
41 inflammation and DNA damage. Receptor-interacting serine/threonine-protein kinase 2 (RIP-  
42 2) is a member of this family and an important component of the nuclear factor NF-kappa-B  
43 signaling pathway. The corresponding human gene *RIPK2* generates two transcripts by  
44 alternative splicing, the full-length and a short transcript. The short transcript has a truncated  
45 5' sequence, which results in a predicted isoform with a partial kinase domain but able to  
46 transduce signals through its caspase recruitment domain. In this study, the expression of  
47 *RIPK2* was investigated in human tissue samples and, in order to determine if both transcripts  
48 are similarly regulated at the transcriptional level, cancer cell lines were submitted to  
49 temperature and acid stresses. We observed that both transcripts are expressed in all tissues  
50 analyzed, with higher expression of the short one in tumor samples, and they are differentially  
51 regulated following temperature stress. Despite transcription, no corresponding protein for the  
52 short transcript was detected in tissues and cell lines analyzed. We propose that the shorter  
53 transcript is a noncoding RNA and that its presence in the cell may play regulatory roles and  
54 affect inflammation and other biological processes related to the kinase activity of RIP-2.

## 56 **Introduction**

57           Unicellular and multicellular organisms are constantly exposed to stressful  
58 environments. Chemical and physical stimuli trigger different adaptive responses, which will  
59 determine the capability of the organism to maintain internal homeostasis [1].

60           Receptor-interacting proteins (RIP) are a family of serine/threonine kinases, which  
61 integrate extra- and intracellular stress signals and share a homologous kinase domain at the  
62 N-terminus, but have different C-terminal functional domains [2-4]; RIP-2 (receptor-  
63 interacting serine/threonine-protein kinase 2) is a member of the RIP family, which has  
64 received attention in the recent years for its role in modulating immune and inflammatory  
65 processes [5], and as a sensor of cellular stress [6]. It is expressed at high levels in several  
66 normal human tissues [7], as well as in pathological conditions, for example ulcerative colitis  
67 [8], triple-negative breast cancers [9,10] and in stressful conditions, such as after  
68 hypoxic/ischemic insults [11]. Conversely, lower levels of RIP-2 have been correlated with  
69 tumor progression in squamous cell carcinoma (SCC) of the oral cavity [12].

70           RIP-2 is the only member of the RIP family that besides phosphorylating serines and  
71 threonines is able to autophosphorylate tyrosine residues [13,14]. Its ATP- and substrate  
72 binding sites spread over much of the N-terminal kinase domain, and a caspase recruitment  
73 domain (CARD) is present in the C-terminal region [15] (isoform 1, Fig 1A). CARD  
74 specifically interacts with the nucleotide-binding oligomerization domain-containing protein 1  
75 (NOD1) and NOD2 (also called CARD-4 and CARD-5, respectively), which are intracellular  
76 receptors for innate immunity and involved in sensing the presence of pathogens. After  
77 activation by bacterial peptidoglycans, NOD1 and NOD2 associate with RIP-2 via CARD-  
78 CARD interaction and promote the expression of immune response and inflammatory genes

79 through the nuclear factor-kappa B (NFkB) signaling [16]. NOD1 and NOD2 also cooperate  
80 and share redundant roles with Toll-like receptors (TLRs) in detecting bacteria, but there's no  
81 consensus on the participation of RIP-2 in TLR signaling (reviewed by [3]). Recently, it has  
82 been demonstrated that RIPK2 kinase activity and auto-phosphorylation are not required for  
83 NOD2 inflammatory signaling. In fact, NOD2 pathway activation and cytokine production  
84 depends on RIP-2 polyubiquitination at several lysines, a process relied on the ubiquitin  
85 ligases:RIP-2 kinase domain interaction. Thus, although the kinase domain is not functionally  
86 important for NOD2 signaling, it is correlated with NOD2 activation since RIP-2 auto-  
87 phosphorylation creates a substrate for ubiquitin ligase binding [17].

88

89 **Fig 1. Diagrams of RIPK2 splice transcripts.** (A) The transcript 1 encodes the longer  
90 isoform and (B) the transcript 2 presents skipping of exon 2 and encodes a very short isoform  
91 2 [18] and a predicted isoform 3. Arrowheads indicate the positions of the forward primer A  
92 and reverse primer B for RT-PCR expression analysis, and horizontal bars below the isoform  
93 1 and 2 indicate the epitope region for anti-RIP-2 ab8428, ab57954 and sc8611 used in the  
94 present study. (C) 5'UTR (lower case) and codons (capital letters) of exons 1, 3 (gray) and 2  
95 (white). Kozak sequences in boxes. First ATGs of full-length isoform and predicted isoform 3  
96 in bold. Premature stop codons generated by the frameshift due to exon 2 skipping=dark gray.  
97 Kinase/K=protein kinase domain; CARD=caspase recruitment domain; activation loop; ATP  
98 binding site; substrate binding site; according to Batch Conserved Domain-Search at NCBI.

99

100 The full-length human *RIPK2* transcript (GenBank accession number NM\_003821.5),  
101 here named transcript 1 (Fig 1A), has 2588 bps and is composed of 12 exons spanning 33-kb  
102 of genomic sequence on chromosome 8q21. In 2004, we suggested an alternative splicing for

103 *RIPK2* transcribing a short variant (AY562996, currently included within the predicted  
104 transcript XM\_005251092.3) [19], as depicted in Fig 1B. This variant, here named transcript  
105 2, has 2389 bps and derives from the skipping of exon 2 (154 bps), which alters the reading  
106 frame producing several premature stop codons. However, a potential translation initiation  
107 codon AUG (nucleotides 85-87 of exon 3) is in-frame with the downstream *RIPK2* sequence,  
108 hence with no subsequent premature termination codon (Fig 1C). Translation from this codon  
109 may give rise to an amino-terminal truncated protein (XP\_005251149.1, isoform 3 in this  
110 study, with 403 residues, predicted molecular weight of 45,582 Da) lacking the first 137  
111 amino acids of RIP-2 isoform 1 (NP\_003812.1).

112 Alternatively spliced transcript 2 was also studied by Krieg and collaborators [18], who  
113 reported a protein product (isoform 2, Fig 1B, top) with extensive truncation of the N-terminal  
114 kinase domain and a complete lack of the intermediate domain and CARD due to a frame shift  
115 generating a premature stop codon. Krieg et al. also reported that this isoform of RIP-2 lacks  
116 the biological effects described for the isoform 1. We here investigated if the use of the  
117 downstream alternative translation initiation site may generate an isoform 3 that would keep  
118 the original C-terminal structure including CARD, but would present a truncated kinase  
119 domain (Fig 1B, bottom), with potential consequences for protein function, and cellular  
120 localization if the localization signals were also deleted.

121 Since RIP-2 kinase integrates extra and intracellular stress signals and modulates  
122 immune responses [5], we reasoned that physiological and environmental changes, such as  
123 hyperthermia and acid stress caused by infections and inflammatory processes, might affect  
124 the expression of their transcripts and, therefore, could lead to changes in levels of the  
125 isoforms depicted in Fig 1. The use of alternative splicing sites may differ among cell types

126 and phases of development [20-23], or be associated with stress conditions, such as  
127 temperature stress [24] and oxidative stress [25].

128 In the present study, the expression of *RIPK2* transcripts and protein products was  
129 evaluated in normal human tissues and in SSC samples and, in order to investigate if they are  
130 regulated in response to stress conditions, we analyzed their expression upon heat/cold and  
131 acid stress in human cancer-derived cell lines.

132

## 133 **Material and methods**

### 134 **Samples and cell lines**

135 Nine samples of normal human tissues removed at autopsy (brain, testis, heart, lung,  
136 stomach, kidney, larynx, liver and tongue) and 16 matched tumor/resection margin samples of  
137 oral SCC were used to evaluate the expression of the two transcripts of the *RIPK2* gene. RIP-2  
138 protein levels were analyzed in another set of 19 matched tumor/resection margin of oral and  
139 laryngeal SCC.

140 For the stress experiments, we used the human cell lines FaDu (HTB-43, derived from  
141 SCC of the hypopharynx), and SiHa (HTB-35, derived from cervix SCC). The cell lines were  
142 cultured in Minimum Essential Medium (MEM, 552, Cultilab), supplemented with 10% fetal  
143 bovine serum (FBS, 63, Cultilab), 10 mM non-essential amino acids (M7145, Sigma), 2 mM  
144 L-glutamine (687, Cultilab), 1 mM sodium pyruvate (P5280, Sigma), 1.5 g/L sodium  
145 bicarbonate (S5761, Sigma), penicillin (100 units/mL) and streptomycin (90 µg/mL) (1012,  
146 Cultilab), in a humidified atmosphere with 5% CO<sub>2</sub> at 37°C. The study protocol was approved  
147 by the National Committee of Ethics in Research (CONEP 1763/05, 18/05/2005, and CONEP  
148 128/12, 02/03/2012) and informed consent was obtained from all patients enrolled.

149

## 150 **Temperature and acid stresses**

151 Prior to stress experiments, cell lines were grown to 80-90% confluence and cell cycle  
152 synchronized in serum-free medium for 24 h. For temperature stress, cells were maintained in  
153 medium plus 10% FBS at 40°C, 17°C or 5°C for 3 h (eight replicates for each condition). Six  
154 control replicas were also cultured in medium plus 10% FBS at 37°C for 3 h. Acidic shock  
155 was performed by maintaining the cultures (four replicas) in an atmosphere with elevated CO<sub>2</sub>  
156 (10% CO<sub>2</sub>) for 24 h or 72 h. Four control replicas were cultured in a humidified atmosphere  
157 with 5% CO<sub>2</sub> at 37°C for the same time period. After the incubation period, cells were  
158 immediately lysed by adding TRIzol (15596026, ThermoFisher), and stored at -80°C until  
159 RNA extraction.

160

## 161 **RNA extraction and cDNA synthesis**

162 Total RNA from tissue samples and cell lines was obtained following the TRIzol  
163 protocol. Integrity of the RNA was confirmed by agarose gel electrophoresis, and the purity  
164 and concentration were determined using the NanoDrop ND-1000 spectrophotometer (Thermo  
165 Fisher). One microgram of total RNA was converted to cDNA using the High Capacity cDNA  
166 Reverse Transcription kit (4368813, Thermo Fisher), according to the manufacturer's  
167 instructions.

168

## 169 **Detection of RIPK2 transcripts by polymerase chain reaction**

170 The PCR amplification of *RIPK2* transcripts was performed using the oligonucleotides  
171 5'-CGCCTCTGGCACTGTGTCGT-3' (forward primer A) and 5'-  
172 CGTGACTGTGAGAGGGACAT-3' (reverse primer B). The PCR reaction was carried out in

173 a total volume of 25  $\mu$ L containing 1X PCR buffer, 1 mM  $MgCl_2$ , 2  $\mu$ M of each *RIPK2*  
174 primer, 2  $\mu$ M *GAPDH* primers, 5 mM dNTPs mix, 1 U Taq DNA polymerase (EP0402,  
175 ThermoFisher) and 50 ng of cDNA. After pre-incubation for 5 min at 94°C (initial  
176 denaturation), the amplification was carried out through 35 cycles at 94°C for 50 s, 58°C for  
177 40 s, 72°C for 50 s, and 72°C for 10 min, using a thermal cycler (9700 GeneAmp PCR  
178 System, Applied Biosystems). PCR primers for the endogenous control gene *GAPDH* were  
179 GAPDHF (5'-ACCCACTCCTCCACCTTTGA-3') and GAPDHR (5'-  
180 CTGTTGCTGTAGCCAAATTCGT-3'). The expected lengths for PCR amplicons were 101  
181 base pairs (bps) for *GAPDH* and 456 or 302 bps for *RIPK2* transcripts. Amplicons were  
182 separated on 2% agarose gels, bands were quantified by densitometry using Image J software,  
183 and sequenced in both directions after being isolated from the gels. The sequences were  
184 analyzed using BLAST similarity search against the non-redundant database available from  
185 the National Center for Biotechnology Information (NCBI) [26].

186

### 187 **Evaluation of *RIPK2* transcripts by relative quantification using RT-qPCR**

188 The expression of *RIPK2* transcripts in matched tumor/resection margin samples and in  
189 cell lines following stress treatment was investigated by quantitative PCR (qPCR). Reactions  
190 were performed in triplicate using an ABI Prism 7500 Sequence Detection System (Applied  
191 Biosystems). The primers were manually designed and optimized for RT-qPCR using basic  
192 parameters for PCR primer design. The final sequences were 19-24-bp long, with 30-70% GC  
193 content and producing a short amplicon size (66-104 bps), as follows: *RIPK2* transcript 1  
194 forward 5'- AGAAGCTGAAATTTTACACAAAGC-3' and reverse 5'-  
195 CCATTTGGCATGTATTCAGTAAC-3'; *RIPK2* transcript 2 forward 5'-  
196 TGCTCGACAGAAAAGTGAATATC-3' and reverse 5'-



197 AAGGAGGAGTCATATTGTGCAG-3'; *GAPDH* forward 5'-  
198 ACCCACTCCTCCACCTTTGA-3' and reverse 5'-CTGTTGCTGTAGCCAAATTCGT-3';  
199 *TUBA1C* forward 5'- TCAACACCTTCTTCAGTGAAACG-3' and reverse 5'-  
200 AGTGCCAGTGCGAACTTCATC-3'; *ACTB* forward 5'-GGCACCCAGCACAATGAAG-3'  
201 and reverse 5'-CCGATCCACACGGAGTACTTG-3'. All primers were purchased from  
202 Invitrogen. Briefly, reactions were carried out in a total volume of 20  $\mu$ L, with 10  $\mu$ L SYBR  
203 Green PCR Master Mix (4385612, ThermoFisher), 250 nM of each primer and 20 ng cDNA.  
204 The PCR conditions were 50°C for 2 min, 95°C for 10 min, followed by 40 cycles of 95°C for  
205 15 s, 58°C for 10 s, 60°C for 1 min. Following PCR, dissociation curve analyses were  
206 performed to confirm the single gene product. Adequate internal control reference genes were  
207 selected using the geNorm algorithm [27] and *TUBA1C* (stress assays) and *ACTB*  
208 (tumor/margin samples) were selected. The relative expression ratio (fold-change) of the  
209 target genes was calculated according to Pfaffl [28]. Statistical analysis was carried out by a  
210 two-tailed unpaired t test using GraphPad Prism (GraphPad Software). Values were Log<sub>2</sub>  
211 transformed and those below -1 indicated down-regulation in gene expression while values  
212 above 1 represented up-regulation in test samples compared with control samples.

213

#### 214 **Protein sequence alignment and homology modeling procedures**

215 Homology modeling of RIP-2 isoforms 1 and 3 was carried out using the MODELLER  
216 software that performs modeling by satisfaction of spatial restraints [29]. Six homologues with  
217 structures available in the Protein Data Bank (codes 2GSF, 1JPA, 1K2P, 1U59, 1UWH,  
218 2EVA) used as templates were selected through a non-redundant BLASTp search [26]. Two  
219 putative conserved domains with statistical significance were detected: TyrKc and S\_TKc,  
220 which correspond, respectively, to the catalytic domains of tyrosine and serine/threonine

221 protein kinases, and include the leucine L10-threonine T296 sequence. These six templates  
222 share sequence identities of 27.1% (Eph receptor tyrosine kinase, PDB code 1JPA) to 30%  
223 [Transforming growth factor-beta (TGF-beta)-activated kinase 1 - TAK1, PDB code 2EVA]  
224 with RIP-2. Analyses were performed using pairwise alignments via the AMPS (Alignment of  
225 Multiple Protein Sequences) package [30]. Previous to the modeling, a final multiple  
226 alignment was obtained by analyzing the superposition of the six structures regarding the  
227 alpha-carbons of the residues, using the INSIGHT II program, version 2005 (Accelrys Inc,  
228 San Diego, CA, USA), which allowed refine the previous alignment obtained from the AMPS  
229 MULTALIGN module. The information of secondary structure in the template sequence was  
230 incorporated into this previous alignment using the MULTALIGN module of the AMPS  
231 package, with the restriction that all insertions and deletions were limited to regions outside  
232 the common core of alpha-helices and beta-sheets. A gap penalty of 1000 was fixed to any  
233 deletion or insertion inside a secondary structure element. The alignment obtained was edited,  
234 investigating and considering the aligned residues, which were close in the space, as  
235 visualized in the structural superposition. This procedure resulted in a final alignment that is  
236 different from the one based on the Dayhoff matrix (PAM 250) used in AMPS.

237 NetPhosK 1.0 server [31] was used for phosphorylation site analyses. The algorithm  
238 produces neural network predictions of kinase-specific eukaryotic protein phosphorylation  
239 sites. Currently, NetPhosK covers the following kinases: PKA, PKC, PKG, CKII, Cdc2, CaM-  
240 II, ATM, DNA PK, Cdk5, p38 MAPK, GSK3, CKI, PKB, RSK, INSR, EGFR, and Src.

241

## 242 **Western blot**

243 Western blot analysis aimed at detecting isoforms 1 and 3. The antibodies used were: (a)  
244 polyclonal anti-RIP2 (ab8428, Abcam), immunogenic peptide corresponding to amino acids

245 11/30 of human RIP-2 (which are only present in isoform 1), N-terminal domain, diluted  
246 2:1000 or 3:1000; (b) monoclonal anti-RIP2 (ab57954; Abcam), immunogenic peptide  
247 corresponding to amino acids 431-541, C-terminal domain, 3 µg/mL; (c) polyclonal anti-  
248 RICK (C-19) (sc8611, Santa Cruz), immunogenic peptide corresponding to C-terminal  
249 domain according to the manufacturer's datasheet, diluted 1:200; (d) monoclonal anti-beta-  
250 actin (A5441, Sigma-Aldrich) diluted 1:5000. The antibodies mapping at C- and N-terminus  
251 of RIP-2 are depicted in Fig 1 (isoforms 1 and 3).

252 In brief, protein samples (30 µg) were loaded onto 12% resolving gel with 5% stacking  
253 gel (SDS-PAGE) in denaturing conditions at 120V for 80 min. The molecular weight ladder  
254 used was the PageRuler Prestained Protein Ladder (#26616; Thermo Scientific). The proteins  
255 were then transferred electrophoretically (162.5 mA per blot 70 min; Mini Protean 3 Cell,  
256 BioRad) to polyvinylidene fluoride (PVDF) membrane (IPVH00010, Immobilon-P, Millipore)  
257 with transfer buffer (25 mM Tris, 0.2 M glycine, 20% v/v methanol; Merck, Germany).  
258 Western blotting was performed using the Amersham ECL Select Western Blotting Detection  
259 Reagent (RPN2235, GE Healthcare, Life Sciences), according to the manufacturer's protocol.  
260 The immunoreactive proteins were visualized using horseradish peroxidase-coupled secondary  
261 antibody (074-1506, 074-1806, KPL, Kirkegaard & Perry Laboratories Inc., Gaithsburg, MD,  
262 USA) and enhanced chemiluminescence reagent (Amersham ECL Select kit, RPN2235, GE  
263 Healthcare). The Fusion FX5 system (Vilber Lourmat) was used for the acquisition of the  
264 signal. The PVDF membranes were also submitted to chromogenic staining using the Western  
265 Breeze kit (Invitrogen). The blots were then scanned and analyzed (Gel Logic HP 2200  
266 imaging system; Carestream Health Inc./Kodak Health Group, Rochester, NY, USA).

267

## 268 **Results**

### 269 **Identification and expression patterns of *RIPK2* transcripts**

270 Alternatively spliced transcripts 1 and 2 of *RIPK2* were co-expressed in normal tissue  
271 samples from brain, testis, heart, lung, stomach, kidney, larynx, liver and tongue (Fig 2A).  
272 Both transcripts were also detected in tumor and tumor free surgical resection samples from  
273 patients with oral SCC as illustrated by 5 matched tumor/surgical margin samples in Fig 2B.  
274 Quantitative real time PCR showed no difference in expression between full length transcript  
275 1 and their respective surgical margins, whereas a significant higher level of shorter transcript  
276 2 was observed ( $p=0.03$ ) (as illustrated by 11 paired samples in Fig 2C).

277

278 **Fig 2. *RIPK2* mRNA expression in normal tissues, oral SCC samples and cell lines under**  
279 **stress conditions. (A-B)** Conventional PCR products from *RIPK2* transcript 1 (456 bps),  
280 transcript 2 (302 bps), and *GAPDH* (101 bps) in: (A) normal human tissues: 1=brain, 2=testis,  
281 3=heart, 4=lung, 5=stomach, 6=kidney, 7=larynx, 8=liver, 9=tongue; (B) samples from  
282 patients with oral cancer: T=tumor; M=resection margin; L=100-bp fragment size marker. (C-  
283 E) RT-qPCR products. (C) Log<sub>2</sub> fold-change of *RIPK2* transcripts showing that transcript 2  
284 has a higher expression than transcript 1 in tumors normalized with matched resection margins  
285 ( $p=0.03$ , unpaired t test). *ACTB* was used as the expression reference. (D) Expression of  
286 *RIPK2* transcript 1 and (E) of transcript 2 in FaDu cells maintained at 5°C, 17°C or 40°C for 3  
287 h, normalized with control cells at 37°C (calibrator sample). Temperature stress induced a  
288 significant increase in transcript 2 expression level at lower temperatures and a decrease at a  
289 higher temperature ( $p<0.0001$ , unpaired t test), but no effect on transcript 1 expression.  
290 *TUBA1C* was used as the expression reference. Values were log<sub>2</sub> transformed (y-axis) so that

291 all values below -1 indicate down-regulation in gene expression while values above 1  
292 represent up-regulation. The error bar represents the mean  $\pm$  S.E.M (standard error of the  
293 mean). Significant differences:  $p < 0.05$ .

294

### 295 **Splicing patterns of *RIPK2* under stress conditions**

296 To investigate whether alternative splicing of *RIPK2* is induced or inhibited by stress  
297 conditions, two cell lines (FaDu and SiHa) were exposed to severe temperature stress (40°C,  
298 17°C and 5°C), and acid stress (atmosphere of 10% CO<sub>2</sub>). Acid stress resulted in no effect on  
299 the expression of both transcripts (data not shown), whereas heat/cold stress induced a  
300 significant increase in shorter transcript 2 expression level at lower temperatures and a  
301 decrease at a higher temperature ( $p < 0.0001$ ), but no effect on full-length transcript 1  
302 expression. This result was only observed in FaDu cells and suggests that distinct regulatory  
303 mechanisms may interfere in the alternative splicing of *RIPK2* and that this may be tissue or  
304 context dependent.

305

### 306 **Protein sequence alignment and homology modeling procedures**

307 The model built for the catalytic domain of isoforms 1 and 3 showed good  
308 stereochemical quality (Fig 3 – kinase domain present only in isoform 1 inside dashed-box;  
309 superposition of the isoform 1 and 3 models outside the box). Despite overall low sequence  
310 identity among the complex structures of the homologue RIP-2 proteins, the active sites are  
311 structurally similar and reasonably well conserved. The model built for the isoform 1 is 137  
312 residues larger than the one obtained for the isoform 3, and includes leucine L10 to threonine  
313 T296 of the overall sequence. Regarding the phosphorylation sites predicted for the isoform 1,  
314 the NetPhosK 1.0 server pointed out 10 sites, which are absent in the isoform 3 sequence:

315 serines at positions 8, 25, 29, 33, 58, 76, 102, and threonines at positions 12, 31, 95. The study  
316 of Dorsch's group [32] suggested that serine S176 is an important autophosphorylation site for  
317 RIP-2, and this phosphorylation can be used to monitor the activation state of RIP-2. Fig 3  
318 shows the superposition of the two models, as well as the localization of serine S176, which  
319 seems to be conveniently accessible to the solvent and to phosphorylation. The lysine K47 in  
320 the conserved ATP-binding site and the critical polyubiquitination site lysine K209 are also  
321 shown in Fig 3.

322

323 **Fig 3. Homology modeling of the catalytic domain of RIP-2 isoforms.** Superposition of the  
324 models built for the RIP-2 isoforms 1 and 3 (ribbon diagram colored in magenta and green,  
325 respectively), with the kinase domain highlighted by the dashed-box (present only in isoform  
326 1), and the superposition of the isoform 1 and 3 models outside the box. Isoform 3 lacks the  
327 first 137 amino acids of RIP-2 and, consequently, the residue critical for kinase activity of  
328 RIP-2 (lysine K47). Ten phosphorylation sites (serine and threonine residues, respectively)  
329 predicted for isoform 1 and absent in isoform 3 sequence are indicated in blue and cyan inside  
330 the dashed box. Serine S176 is shown in yellow stick, and is indicated to be conveniently  
331 accessible to the solvent and to phosphorylation. Lysines K47 and K209 are also shown in  
332 colored sticks.

333

### 334 **Immunodetection of RIP-2 isoforms**

335 Western blot analysis detected RIP-2 protein in extracts derived from FaDu cell line  
336 and from human tumors and their resection margins (Fig 4). The best results were obtained  
337 with the N-terminal domain anti-RIP2 ab8428 and C-terminal anti-RICK sc8611 antibodies,  
338 whereas ab57954 antibody yielded weak or non-specific bands. In cell line samples, Western

339 blot demonstrated a single immunoreactive band at ~61 kDa, consistent with the molecular  
340 weight of the isoform 1 (61,195 Da). When cells were exposed to heat/cold stress, a lower  
341 expression of the RIP-2 isoform 1 was observed in FaDu cells maintained at low temperatures  
342 compared with control cells at 37°C (Fig 4A).

343 Isoform 3 (predicted molecular weight of 45,582 Da) was not detected both in cell  
344 lines and normal or neoplastic tissue samples (Fig 4A, 4B), even after mass spectrometry  
345 analysis of Western blot band corresponding to the region around 45 kDa (data not shown).  
346 The result indicates that, despite the detection of transcripts 1 and 2 and the proteins predicted  
347 *in silico* for the isoforms, alternatively spliced transcript 2 does not seem to be translated into  
348 protein in normal human tissues, cancer samples or cell lines analyzed.

349

350 **Fig 4. RIP-2 expression in cell lines under stress conditions and in oral SCC samples.**

351 Western blot illustrating (A) lower expression of the RIP-2 isoform 1 (~61 kDa) in FaDu cells  
352 maintained at low temperatures compared with control cells at 37°C (anti-RIP-2 ab8428  
353 against N-terminus); and (B) an apparent decreased expression of the RIP-2 isoform 1 in  
354 tumor (T) than in resection margin (M) samples (anti-RIP-2 sc8611 against C-terminus). (A-  
355 B) No band that corresponds to isoform 3 was observed. Data were normalized by beta-actin.  
356 L = Protein Ladder.

357

358 **Discussion**

359 In the present study, *RIPK2* transcripts 1 and 2 were co-expressed in normal tissue  
360 samples from brain, testis, heart, lung, stomach, kidney, larynx, liver and tongue. Our stress  
361 experiments showed that one of the transcripts (transcript 2) is up-regulated at low

362 temperatures compared with the control group (at 37°C), whereas the opposite occurs at 40°C.  
363 We tested two distinct SCC-derived cell lines, but this effect was seen only in FaDu cell line.  
364 This finding may be tissue/context dependent. In fact, literature has already referred that a  
365 mild hypothermic condition appears to induce or to inhibit synthesis of specific proteins when  
366 compared with control cells, an effect that is cell line dependent (reviewed by [33]. It's well  
367 known that both prokaryotic and eukaryotic organisms respond to cold stress reducing  
368 transcription, translation, and metabolic processes, except in the case of cold-shock proteins  
369 [34].

370 Many studies are available on alternative splicing regulation by temperature and other  
371 extrinsic agents. For example, Gemignani and collaborators [35] also observed a shift in  
372 splicing of a mutated human b-globin gene affected by temperature *in vitro*, which led the  
373 authors to propose temperature changes as a treatment for  $\beta$ -thalassemia. More recently,  
374 Farashahi Yazd's group [24] described a novel spliced variant of *OCT4* gene significantly  
375 elevated under heat-stress conditions, and proposed a potential role of OCT4B1 transcript and  
376 protein in mediating temperature response.

377 Yan and collaborators [36] found evidence that hyperthermia induces Toll-like receptors  
378 expression and TLR signaling-mediated activation of NFKB and MAPK pathways, resulting  
379 in increased synthesis of pro- and anti-inflammatory cytokines. These data suggest that fever  
380 may modulate innate immune responses by TLR pathway and, although the role of *RIPK2* in  
381 this signaling remains controversial [37-40], they provide a possible link to *RIPK2* expression  
382 changes depending on the temperature variation.

383 Considering these data, we hypothesize that, under stress conditions, a putative  
384 mechanism may induce higher or lower expression of the exon 2-containing transcript of



385 *RIPK2*. Since the presumed isoform 3 has a truncated kinase domain but is potentially able to  
386 mediate NF $\kappa$ B activation via CARD, the balance of isoforms 1 and 3 might affect signaling  
387 pathways related to its kinase activity. For instance, hyperthermia may increase the alternative  
388 splicing kinetics or alter transcript stability and affect ERK pathways. A dominant-negative  
389 mechanism by the truncated isoform should not be excluded [41]. DNA-damaging or altered  
390 expression/subcellular distribution of RNA processing regulators [42] caused by temperature  
391 changes may also be responsible for the abnormal accumulation of alternatively spliced  
392 transcripts. These hypotheses obviously require experimental confirmation.

393 In the present study, *RIPK2* transcripts also showed a different expression pattern in  
394 samples from head and neck squamous cell carcinoma patients, with alternatively spliced  
395 transcript 2 exhibiting higher expression in tumors compared to their respective surgical  
396 margins. Differences in alternative splicing between tumor and normal samples have been  
397 described in the literature. For example, Gracio et al. [43], using ExonArray analysis of breast  
398 cancer and normal breast tissue samples, identified more than 200 genes with splicing  
399 differences associated with clinical outcome. Bjørklund et al. [44] obtained similar results by  
400 RNA-seq analysis in primary breast tumors for five genes. The large study of Kahles et al.  
401 analyzed 32 cancer types, including head and neck cancers, using RNA and whole-exome  
402 sequencing data and observed many differences in alternative splicing events in cancer  
403 compared with normal cells [45]. Specifically in regard to head and neck cancer, several other  
404 groups have described genes with differential expression of spliced variants [46-50]; among  
405 others). However, as far as we know, this is the first report showing differential expression of  
406 spliced transcripts of *RIPK2* gene between tumor and normal tissues.

407 At the protein level, decreased expression of the RIP-2 isoform 1 (immunoreactive band  
408 at ~61 kDa) was detected at low temperatures, disagreeing with our findings for full-length

409 transcript 1, which showed no change at the same condition compared to the control. A  
410 divergent pattern was also observed for transcript 1 and the corresponding isoform 1 in  
411 neoplastic tissues, the former showing higher and the second lower levels in tumor samples  
412 compared with resection margins. This apparent discordance can be explained by the fact that  
413 protein abundance may differ from mRNA expression profile, mainly due to post-  
414 transcriptional control of gene expression or protein half-lives [51,52]. In addition, confirming  
415 our results from immunodetection assays, Wang and collaborators [12] also found reduced  
416 levels of RIP-2 in oral SCCs using immunohistochemical techniques.

417 In spite of using three distinct antibodies, another divergent result between RNA and  
418 protein expression was the absence of isoform 3, which suggests that translation of *RIPK2* into  
419 isoform 3 may not happen, at least in cell and tissue types analyzed in this study.

420 If the predicted alternative isoform 3 of RIP-2 is present in other conditions and tissue,  
421 then it should exhibit some impaired functions related to its kinase domain, including NFKB  
422 activation [5] [15,17,53], regulation of ERKs, p38 kinases, and own degradation [5,17,37,54].

423 Recently, Brady et al. identified a dominant-negative isoform of the translation initiation  
424 factor eIF-2B created by a hypoxia-mediated intron retention that inhibits translation and  
425 increases survival of neoplastic cells [50]. Dasgupta and collaborators [55] also described a C-  
426 terminal fragment of a member of RIP family, RIP-1, which can activate signaling events  
427 including NFKB and TNF pathways. They concluded that short RIP-1 with an aberrant N-  
428 terminal affects the long isoform levels and may represent a new regulation mechanism.

429 Albeit exhibiting some differences, RIP-1 and -2 participate in the same regulatory pathway  
430 and therefore RIP-2 isoform also may have a similar function and modulate full-length RIP-2  
431 under different conditions.

432 It is tempting to speculate that the Krieg ORF [18] could act as an uORF (upstream  
433 ORF) and repress translation of the downstream isoform 3 ORF, as cited for several stress  
434 response mRNAs by the literature [56,57]. The short intercistronic region between both ORFs  
435 should not be favorable for translation reinitiation due to an insufficient ribosomal scanning  
436 time necessary for reacquisition of the ternary complex (eIF2-GTP-Met-tRNA<sub>i</sub>) and for the  
437 downstream AUG recognition [58]. Translation reinitiation also depends on the Kozak  
438 context. Using numeric scores based on translation initiation site efficiencies determined in  
439 mammalian cells by Noderer et al.[59], both full-length and short RIP-2 transcripts have good  
440 efficiency values (90 and 107, respectively), but the predicted ratio of the initiation occurring  
441 at the second site compared to the first one is low ( $< 0.005$ ), which may justify the absence of  
442 isoform 3.

443 As RIP kinases play a critical role in integrating stress signals, the elucidation of the  
444 factors that take part in the regulation of these proteins is of major importance. The alternative  
445 transcripts and protein isoforms may be tissue and context dependent and related to important  
446 disease responses [41].

447 Although the *RIPK2* transcript 2 has a coding potential, at present there is no direct  
448 evidence that it is translated in the isoform 3 or that it regulates biological processes, by  
449 competing with other molecules or modulating stress responses. Even without clarifying these  
450 issues, the present study raises many questions about RNA biology that may stimulate further  
451 functional investigation on the molecular mechanisms underlying *RIPK2* splicing regulation  
452 and their links to physiological and environmental changes.

453

## 454 **Conclusions**

455 In conclusion, *RIPK2* transcripts 1 and 2 are expressed in different tissues and  
456 modulated by temperature, as determined by quantitative PCR assays. As far as we know, this  
457 is the first report showing splicing imbalances between tumor and normal samples of *RIPK2*  
458 gene, an important immune and inflammatory modulator. Despite transcription, no  
459 corresponding protein for the short isoform was detected in tissues and cell lines analyzed,  
460 which suggests that the balance of both transcripts may play regulatory roles and affect  
461 inflammation and other biological processes related to the activity of RIP-2.

462

## 463 **Acknowledgements**

464 The authors thank the Fundação de Amparo à Pesquisa do Estado de São Paulo/FAPESP  
465 (FAPESP grant numbers 04/12054-9 and 10/51168-0) and Conselho Nacional de  
466 Pesquisas/CNPq (CNPq grant number 308904/2014-1) for financial support and fellowships.  
467 They are also grateful to Mauro Golin and Edilson Solim for artwork preparation, and to  
468 GENCAPO (Head and Neck Genome Project—<http://www.gencapo.famerp.br/>) team for the  
469 valuable discussions that motivated the present study.

470

## 471 **References**

- 472 1. de Nadal E, Ammerer G, Posas F (2011) Controlling gene expression in response to stress. *Nat*  
473 *Rev Genet* 12: 833-845.
- 474 2. Zhang D, Lin J, Han J (2010) Receptor-interacting protein (RIP) kinase family. *Cell Mol*  
475 *Immunol* 7: 243-249.
- 476 3. Humphries F, Yang S, Wang B, Moynagh PN (2015) RIP kinases: key decision makers in cell  
477 death and innate immunity. *Cell Death Differ* 22: 225-236.
- 478 4. He S, Wang X (2018) RIP kinases as modulators of inflammation and immunity. *Nat Immunol*  
479 19: 912-922.
- 480 5. Hasegawa M, Fujimoto Y, Lucas PC, Nakano H, Fukase K, et al. (2008) A critical role of  
481 RICK/RIP2 polyubiquitination in Nod-induced NF-kappaB activation. *EMBO J* 27: 373-  
482 383.

- 483 6. Meylan E, Tschopp J (2005) The RIP kinases: crucial integrators of cellular stress. Trends  
484 Biochem Sci 30: 151-159.
- 485 7. McCarthy JV, Ni J, Dixit VM (1998) RIP2 is a novel NF-kappaB-activating and cell death-  
486 inducing kinase. J Biol Chem 273: 16968-16975.
- 487 8. Stronati L, Negroni A, Pierdomenico M, D'Ottavio C, Tirindelli D, et al. (2010) Altered  
488 expression of innate immunity genes in different intestinal sites of children with  
489 ulcerative colitis. Dig Liver Dis 42: 848-853.
- 490 9. Singel SM, Batten K, Cornelius C, Jia G, Fasciani G, et al. (2014) Receptor-interacting protein  
491 kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation  
492 of nuclear factor-kappaB and c-Jun N-terminal kinase pathways. Breast Cancer Res 16:  
493 R28.
- 494 10. Jaafar R, Mnich K, Dolan S, Hillis J, Almanza A, et al. (2018) RIP2 enhances cell survival by  
495 activation of NF-kB in triple negative breast cancer cells. Biochem Biophys Res Commun  
496 497: 115-121.
- 497 11. Zhang WH, Wang X, Narayanan M, Zhang Y, Huo C, et al. (2003) Fundamental role of the  
498 Rip2/caspase-1 pathway in hypoxia and ischemia-induced neuronal cell death. Proc Natl  
499 Acad Sci U S A 100: 16012-16017.
- 500 12. Wang X, Jiang W, Duan N, Qian Y, Zhou Q, et al. (2014) NOD1, RIP2 and Caspase12 are  
501 potentially novel biomarkers for oral squamous cell carcinoma development and  
502 progression. Int J Clin Exp Pathol 7: 1677-1686.
- 503 13. Tigno-Aranjuez JT, Asara JM, Abbott DW (2010) Inhibition of RIP2's tyrosine kinase  
504 activity limits NOD2-driven cytokine responses. Genes Dev 24: 2666-2677.
- 505 14. Chirieleison SM, Kertesy SB, Abbott DW (2016) Synthetic Biology Reveals the Uniqueness  
506 of the RIP Kinase Domain. J Immunol 196: 4291-4297.
- 507 15. Inohara N, del Peso L, Koseki T, Chen S, Nunez G (1998) RICK, a novel protein kinase  
508 containing a caspase recruitment domain, interacts with CLARP and regulates CD95-  
509 mediated apoptosis. J Biol Chem 273: 12296-12300.
- 510 16. Inohara N, Nunez G (2003) NODs: intracellular proteins involved in inflammation and  
511 apoptosis. Nat Rev Immunol 3: 371-382.
- 512 17. Goncharov T, Hedayati S, Mulvihill MM, Izrael-Tomasevic A, Zobel K, et al. (2018)  
513 Disruption of XIAP-RIP2 Association Blocks NOD2-Mediated Inflammatory Signaling.  
514 Mol Cell 69: 551-565 e557.
- 515 18. Krieg A, Le Negrate G, Reed JC (2009) RIP2-beta: a novel alternative mRNA splice variant  
516 of the receptor interacting protein kinase RIP2. Mol Immunol 46: 1163-1170.
- 517 19. Mancini U, Tajara E (2004) Transcript variant of RIPK2 gene in tumoral cell lines (FaDu,  
518 HEp2, HeLa, SiHa). In: Information NCfB, editor.
- 519 20. Zeng Z, Sharpe CR, Simons JP, Gorecki DC (2006) The expression and alternative splicing  
520 of alpha-neurexins during Xenopus development. Int J Dev Biol 50: 39-46.
- 521 21. Szafranski K, Kramer M (2015) It's a bit over, is that ok? The subtle surplus from tandem  
522 alternative splicing. RNA Biol 12: 115-122.
- 523 22. Gutierrez-Arcelus M, Ongen H, Lappalainen T, Montgomery SB, Buil A, et al. (2015)  
524 Tissue-specific effects of genetic and epigenetic variation on gene regulation and splicing.  
525 PLoS Genet 11: e1004958.
- 526 23. Reber S, Stettler J, Filosa G, Colombo M, Jutzi D, et al. (2016) Minor intron splicing is  
527 regulated by FUS and affected by ALS-associated FUS mutants. EMBO J 35: 1504-1521.

- 528 24. Farashahi Yazd E, Rafiee MR, Soleimani M, Tavallaei M, Salmani MK, et al. (2011)  
529 OCT4B1, a novel spliced variant of OCT4, generates a stable truncated protein with a  
530 potential role in stress response. *Cancer Lett* 309: 170-175.
- 531 25. Cote GJ, Zhu W, Thomas A, Martin E, Murad F, et al. (2012) Hydrogen peroxide alters  
532 splicing of soluble guanylyl cyclase and selectively modulates expression of splicing  
533 regulators in human cancer cells. *PLoS One* 7: e41099.
- 534 26. Johnson M, Zaretskaya I, Raytselis Y, Merezhuk Y, McGinnis S, et al. (2008) NCBI BLAST:  
535 a better web interface. *Nucleic Acids Res* 36: W5-9.
- 536 27. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, et al. (2002) Accurate  
537 normalization of real-time quantitative RT-PCR data by geometric averaging of multiple  
538 internal control genes. *Genome Biol* 3: RESEARCH0034.
- 539 28. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-  
540 PCR. *Nucleic Acids Res* 29: e45.
- 541 29. Sali A, Blundell TL (1990) Definition of general topological equivalence in protein  
542 structures. A procedure involving comparison of properties and relationships through  
543 simulated annealing and dynamic programming. *J Mol Biol* 212: 403-428.
- 544 30. Barton GJ, Sternberg MJ (1987) A strategy for the rapid multiple alignment of protein  
545 sequences. Confidence levels from tertiary structure comparisons. *J Mol Biol* 198: 327-  
546 337.
- 547 31. Blom N, Sicheritz-Ponten T, Gupta R, Gammeltoft S, Brunak S (2004) Prediction of post-  
548 translational glycosylation and phosphorylation of proteins from the amino acid sequence.  
549 *Proteomics* 4: 1633-1649.
- 550 32. Dorsch M, Wang A, Cheng H, Lu C, Bielecki A, et al. (2006) Identification of a regulatory  
551 autophosphorylation site in the serine-threonine kinase RIP2. *Cell Signal* 18: 2223-2229.
- 552 33. Tait AS, Tarrant RD, Velez-Suberbie ML, Spencer DI, Bracewell DG (2013) Differential  
553 response in downstream processing of CHO cells grown under mild hypothermic  
554 conditions. *Biotechnol Prog* 29: 688-696.
- 555 34. Hrdinka M, Schlicher L, Dai B, Pinkas DM, Bufton JC, et al. (2018) Small molecule  
556 inhibitors reveal an indispensable scaffolding role of RIPK2 in NOD2 signaling. *EMBO J*  
557 37.
- 558 35. Gemignani F, Sazani P, Morcos P, Kole R (2002) Temperature-dependent splicing of beta-  
559 globin pre-mRNA. *Nucleic Acids Res* 30: 4592-4598.
- 560 36. Yan X, Xiu F, An H, Wang X, Wang J, et al. (2007) Fever range temperature promotes TLR4  
561 expression and signaling in dendritic cells. *Life Sci* 80: 307-313.
- 562 37. Chin AI, Dempsey PW, Bruhn K, Miller JF, Xu Y, et al. (2002) Involvement of receptor-  
563 interacting protein 2 in innate and adaptive immune responses. *Nature* 416: 190-194.
- 564 38. Kobayashi K, Inohara N, Hernandez LD, Galan JE, Nunez G, et al. (2002)  
565 RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive  
566 immune systems. *Nature* 416: 194-199.
- 567 39. Park JH, Kim YG, McDonald C, Kanneganti TD, Hasegawa M, et al. (2007) RICK/RIP2  
568 mediates innate immune responses induced through Nod1 and Nod2 but not TLRs. *J*  
569 *Immunol* 178: 2380-2386.
- 570 40. Hall HT, Wilhelm MT, Saibil SD, Mak TW, Flavell RA, et al. (2008) RIP2 contributes to  
571 Nod signaling but is not essential for T cell proliferation, T helper differentiation or TLR  
572 responses. *Eur J Immunol* 38: 64-72.
- 573 41. Barrie ES, Smith RM, Sanford JC, Sadee W (2012) mRNA transcript diversity creates new  
574 opportunities for pharmacological intervention. *Mol Pharmacol* 81: 620-630.




- 575 42. Busa R, Geremia R, Sette C (2010) Genotoxic stress causes the accumulation of the splicing  
576 regulator Sam68 in nuclear foci of transcriptionally active chromatin. *Nucleic Acids Res*  
577 38: 3005-3018.
- 578 43. Gracio F, Burford B, Gazinska P, Mera A, Mohd Noor A, et al. (2017) Splicing imbalances in  
579 basal-like breast cancer underpin perturbation of cell surface and oncogenic pathways and  
580 are associated with patients' survival. *Sci Rep* 7: 40177.
- 581 44. Bjorklund SS, Panda A, Kumar S, Seiler M, Robinson D, et al. (2017) Widespread alternative  
582 exon usage in clinically distinct subtypes of Invasive Ductal Carcinoma. *Sci Rep* 7: 5568.
- 583 45. Kahles A, Lehmann KV, Toussaint NC, Huser M, Stark SG, et al. (2018) Comprehensive  
584 Analysis of Alternative Splicing Across Tumors from 8,705 Patients. *Cancer Cell* 34:  
585 211-224 e216.
- 586 46. Sam KK, Gan CP, Yee PS, Chong CE, Lim KP, et al. (2012) Novel MDM2 splice variants  
587 identified from oral squamous cell carcinoma. *Oral Oncol* 48: 1128-1135.
- 588 47. Liborio TN, Ferreira EN, Aquino Xavier FC, Carraro DM, Kowalski LP, et al. (2013) TGIF1  
589 splicing variant 8 is overexpressed in oral squamous cell carcinoma and is related to  
590 pathologic and clinical behavior. *Oral Surg Oral Med Oral Pathol Oral Radiol* 116: 614-  
591 625.
- 592 48. Palve V, Mallick S, Ghaisas G, Kannan S, Teni T (2014) Overexpression of Mcl-1L splice  
593 variant is associated with poor prognosis and chemoresistance in oral cancers. *PLoS One*  
594 9: e111927.
- 595 49. Radhakrishnan A, Nanjappa V, Raja R, Sathe G, Chavan S, et al. (2016) Dysregulation of  
596 splicing proteins in head and neck squamous cell carcinoma. *Cancer Biol Ther* 17: 219-  
597 229.
- 598 50. Brady LK, Wang H, Radens CM, Bi Y, Radovich M, et al. (2017) Transcriptome analysis of  
599 hypoxic cancer cells uncovers intron retention in EIF2B5 as a mechanism to inhibit  
600 translation. *PLoS Biol* 15: e2002623.
- 601 51. Greenbaum D, Colangelo C, Williams K, Gerstein M (2003) Comparing protein abundance  
602 and mRNA expression levels on a genomic scale. *Genome Biol* 4: 117.
- 603 52. Kuchta K, Towpik J, Biernacka A, Kutner J, Kudlicki A, et al. (2018) Predicting proteome  
604 dynamics using gene expression data. *Sci Rep* 8: 13866.
- 605 53. Inohara N, Koseki T, Lin J, del Peso L, Lucas PC, et al. (2000) An induced proximity model  
606 for NF-kappa B activation in the Nod1/RICK and RIP signaling pathways. *J Biol Chem*  
607 275: 27823-27831.
- 608 54. Navas TA, Baldwin DT, Stewart TA (1999) RIP2 is a Raf1-activated mitogen-activated  
609 protein kinase kinase. *J Biol Chem* 274: 33684-33690.
- 610 55. Dasgupta M, Agarwal MK, Varley P, Lu T, Stark GR, et al. (2008) Transposon-based  
611 mutagenesis identifies short RIP1 as an activator of NFkappaB. *Cell Cycle* 7: 2249-2256.
- 612 56. Spriggs KA, Bushell M, Willis AE (2010) Translational regulation of gene expression during  
613 conditions of cell stress. *Mol Cell* 40: 228-237.
- 614 57. Andreev DE, Arnold M, Kiniry SJ, Loughran G, Michel AM, et al. (2018) TASEP modelling  
615 provides a parsimonious explanation for the ability of a single uORF to derepress  
616 translation during the integrated stress response. *Elife* 7.
- 617 58. Kozak M (1987) Effects of intercistronic length on the efficiency of reinitiation by eucaryotic  
618 ribosomes. *Mol Cell Biol* 7: 3438-3445.
- 619 59. Noderer WL, Flockhart RJ, Bhaduri A, Diaz de Arce AJ, Zhang J, et al. (2014) Quantitative  
620 analysis of mammalian translation initiation sites by FACS-seq. *Mol Syst Biol* 10: 748.
- 621






## A *RIPK2* - transcript 1



## B *RIPK2* - transcript 2



bioRxiv preprint doi: <https://doi.org/10.1101/466011>; this version posted November 8, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

## C

### Exon 1

gagctcgggcgccggagctggtcgctgcgcgcgcccggggggagggccggggctgagagagaggaagctctttcg  
 cggcgctacggcgttggcaccagtctctagaaaagaagtcagctctggttcggagaagcagcggctggcgtgggcat  
 ccggggaatgggcgccctcgtgacctagtgtgcggggcaaaaagggtcttgcggcctcgtcgtgcagggcgat  
 ctgggcgctgagcgcggcgtgggagccttgggagccgcagcagggggcacacccggaaccggcctgagcg  
 ccggggacc **ATG AAC** GGG GAG GCC ATC TGC AGC GCC CTG CCC ACC ATT CCC  
 TAC CAC AAA CTC GCC GAC CTG CGC TAC CTG AGC CGC GGC GCC TCT GGC  
 ACT GTG TCG TCC GCC CGC CAC GCA GAC TGG CGC GTC CAG GTG GCC GTG  
 AAG CAC CTG CAC ATC CAC ACT CCG CTG CTC GAC AG

### Exon 2

T GAA AGA AAG GAT GTC TTA AGA GAA GCT GAA ATT TTA CAC AAA GCT AGA  
 TTT AGT TAC ATT CTT CCA ATT TTG GGA ATT TGC AAT GAG CCT GAA TTT TTG  
 GGA ATA GTT ACT GAA TAC ATG CCA AAT GGA TCA TTA AAT GAA CTC CTA CAT  
 AGG

### Exon 3

AAA ACT GAA TAT CCT GAT GTT GCT TGG CCA TTG AGA TTT CGC ATC CTG CAT  
 GAA ATT GCC CTT GGT GTA AAT TAC CTG **CAC AAT ATG ACT** CCT CCT TTA CTT  
 CAT CAT GAC TTG AAG ACT CAG AAT ATC TTA TTG GAC AAT GAA TTT CAT GTT  
 AAG




Fig3






Fig4







Fig2